Latest News
Aerogen finalises Management Buy Out from Nektar Therapeutics
Galway, Ireland, 15th January, 2008: Medical device firm Aerogen has completed a management buyout (MBO) from its US parent, Nektar Therapeutics for an undisclosed amount. Aerogen specializes in drug delivery technology for the respiratory sector.
Aerogen’s core technology, the OnQ™ micropump aerosol generator is currently used worldwide in nebulizers for drug delivery to patients in the intensive care and homecare settings. Distributed by industry leaders such as Respironics, GE Healthcare, Maquet, Covidien and an independent distributor network, Aerogen’s products are available in over 50 countries. Key markets include the US, Japan and Germany.
“This deal empowers Aerogen to grow our business and expand our product offerings,” commented John Power, CEO, Aerogen. Aerogen has advanced negotiations in several exciting areas and plans to announce new partnerships with a number of US and European market leaders in both the medical field and commercial products area in the near future.
With headquarters in Galway, Ireland, Aerogen also has offices in the UK and America. Under the terms of the deal, Nektar will maintain a minority share in the business.
